BSE Live
Dec 27, 11:22Prev. Close
2.05
Open Price
-
Bid Price (Qty.)
- (0)
Offer Price (Qty.)
- (0)
NSE Live
Dec 27, 11:22Prev. Close
-
Open Price
-
Bid Price (Qty.)
- (0)
Offer Price (Qty.)
- (0)
| Key Financial Ratios of Pan Drugs (in Rs. Cr.) | Mar 15 | Mar 13 | Mar 12 | Mar 11 | |
| Per Share Ratios | |||||
| Basic EPS (Rs.) | -0.19 | -0.54 | -1.86 | 2.49 | |
| Diluted EPS (Rs.) | -0.19 | -0.87 | -3.00 | 4.35 | |
| Cash EPS (Rs.) | 0.00 | 0.78 | -1.55 | 5.67 | |
| Book Value [ExclRevalReserve]/Share (Rs.) | 0.00 | -26.90 | -26.02 | -23.02 | |
| Book Value [InclRevalReserve]/Share (Rs.) | 0.00 | -26.90 | -26.02 | -23.02 | |
| Dividend / Share(Rs.) | 0.00 | 0.00 | 0.00 | 0.00 | |
| Revenue from Operations/Share (Rs.) | 0.00 | 61.62 | 62.87 | 113.24 | |
| PBDIT/Share (Rs.) | 0.00 | 0.92 | -1.33 | 6.42 | |
| PBIT/Share (Rs.) | 0.00 | -0.73 | -2.79 | 5.10 | |
| PBT/Share (Rs.) | 0.00 | -0.87 | -3.00 | 4.35 | |
| Net Profit/Share (Rs.) | 0.00 | -0.87 | -3.00 | 4.35 | |
| Profitability Ratios | |||||
| PBDIT Margin (%) | 3.39 | 1.49 | -2.11 | 5.67 | |
| PBIT Margin (%) | -0.04 | -1.18 | -4.43 | 4.50 | |
| PBT Margin (%) | -0.16 | -1.41 | -4.77 | 3.84 | |
| Net Profit Margin (%) | -0.16 | -1.41 | -4.77 | 3.84 | |
| Return on Networth / Equity (%) | 0.00 | 3.24 | 11.54 | -18.89 | |
| Return on Capital Employed (%) | 0.00 | 3.86 | 13.71 | -23.53 | |
| Return on Assets (%) | 0.00 | -1.41 | -4.73 | 6.57 | |
| Total Debt/Equity (X) | 0.00 | -2.32 | -2.37 | -2.55 | |
| Asset Turnover Ratio (%) | 0.00 | 99.99 | 99.00 | 171.08 | |
| Liquidity Ratios | |||||
| Current Ratio (X) | 0.00 | 0.39 | 0.42 | 0.51 | |
| Quick Ratio (X) | 0.00 | 0.31 | 0.33 | 0.34 | |
| Inventory Turnover Ratio (X) | 0.00 | 8.92 | 8.88 | 8.02 | |
| Dividend Payout Ratio (NP) (%) | 0.00 | 0.00 | 0.00 | 0.00 | |
| Dividend Payout Ratio (CP) (%) | 0.00 | 0.00 | 0.00 | 0.00 | |
| Earnings Retention Ratio (%) | 0.00 | 0.00 | 0.00 | 0.00 | |
| Cash Earnings Retention Ratio (%) | 0.00 | 0.00 | 0.00 | 0.00 | |
| Valuation Ratios | |||||
| Enterprise Value (Cr.) | 0.00 | 0.00 | 0.00 | 0.00 | |
| EV/Net Operating Revenue (X) | 0.00 | 0.00 | 0.00 | 0.00 | |
| EV/EBITDA (X) | 0.00 | 0.00 | 0.00 | 0.00 | |
| MarketCap/Net Operating Revenue (X) | 0.00 | 0.00 | 0.00 | 0.00 | |
| Retention Ratios (%) | 0.00 | 0.00 | 0.00 | 0.00 | |
| Price/BV (X) | 0.00 | 0.00 | 0.00 | 0.00 | |
| Price/Net Operating Revenue | 0.00 | 0.00 | 0.00 | 0.00 | |
| Earnings Yield | 0.00 | 0.00 | 0.00 | 0.00 |
02.04.2026
02.04.2026
Lupin shares down 2% as arm to acquire 43.38% stake in Multicare Pharma
02.04.2026
02.04.2026
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth